HighTower Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

HighTower Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-47,169	Closed	-$3.71M	–	3714
2023 Q2	$3.71M	Buy	+47,169	New	+$3.69M	0.01%	1043
2016 Q1	–	Sell	-3,546	Closed	-$232K	–	2171
2015 Q4	$232K	Buy	3,546 +300	+9%	+$19.4K	﹤0.01%	1689
2015 Q3	$202K	Sell	3,246 -49,690	-94%	-$3.49M	﹤0.01%	1637
2015 Q2	$3.75M	Buy	52,936 +14,299	+37%	+$1.03M	0.06%	346
2015 Q1	$2.71M	Sell	38,637 -49,091	-56%	-$3.33M	0.04%	491
2014 Q4	$5.64M	Buy	87,728 +2,334	+3%	+$149K	0.09%	251
2014 Q3	$5.43M	Buy	85,394 +2,556	+3%	+$158K	0.09%	253
2014 Q2	$5.15M	Buy	82,838 +47,210	+133%	+$2.81M	0.09%	249
2014 Q1	$2.09M	Buy	+35,628	New	+$2.01M	0.04%	502

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

PCIA

Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

HighTower Advisors's PPH Position: Q3 2023 in Review

HighTower Advisors sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2023, closing a stake of 47,169 shares — an estimated $3.71M sold.

HighTower Advisors first reported a position in PPH in Q1 2014 and held it in 9 quarters. The position peaked at $5.64M in Q4 2014. 102 funds tracked by Wall St. Rank hold PPH as of Q3 2023.

HighTower Advisors reported no remaining VanEck Pharmaceutical ETF position as of Q3 2023 after selling out during the quarter.
HighTower Advisors sold 47,169 VanEck Pharmaceutical ETF shares in Q3 2023, an estimated $3.71M.
HighTower Advisors first reported a position in VanEck Pharmaceutical ETF in Q1 2014 and held it in 9 quarters.
HighTower Advisors's VanEck Pharmaceutical ETF position peaked at $5.64M in Q4 2014.
102 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2023.

Based on HighTower Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.